{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:16:25Z","timestamp":1788560185245,"version":"build-2803163510"},"reference-count":2,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"26","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.1200\/jco-26-00940","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:00:18Z","timestamp":1783454418000},"page":"2558-2560","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-3734","authenticated-orcid":false,"given":"Nadine M.","family":"Tung","sequence":"first","affiliation":[{"name":"Nadine M. Tung, MD, FASCO, Dana-Farber Cancer Institute, Boston, MA; Tianyu Li, MS, Dana-Farber Cancer Institute, Boston, MA; and Judy E. Garber, MD, MPH, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[{"name":"Nadine M. Tung, MD, FASCO, Dana-Farber Cancer Institute, Boston, MA; Tianyu Li, MS, Dana-Farber Cancer Institute, Boston, MA; and Judy E. Garber, MD, MPH, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-3982","authenticated-orcid":false,"given":"Judy E.","family":"Garber","sequence":"additional","affiliation":[{"name":"Nadine M. Tung, MD, FASCO, Dana-Farber Cancer Institute, Boston, MA; Tianyu Li, MS, Dana-Farber Cancer Institute, Boston, MA; and Judy E. Garber, MD, MPH, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","unstructured":"Yan J Xiong W Cai H. Olaparib in metastatic breast cancer: The impact of prior cyclin-dependent kinase 4 and 6 inhibitor exposure on efficacy. J Clin Oncol 44:2557-2558 2026","DOI":"10.1200\/JCO-26-00539"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02075"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-26-00940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:59:26Z","timestamp":1788559166000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-26-00940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":2,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2026,9,10]]}},"alternative-id":["10.1200\/JCO-26-00940"],"URL":"https:\/\/doi.org\/10.1200\/jco-26-00940","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2026-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}